{"id":493986,"date":"2024-01-23T04:16:50","date_gmt":"2024-01-23T09:16:50","guid":{"rendered":"https:\/\/platohealth.ai\/strand-therapeutics-given-clearance-for-solid-tumour-drug-trial\/"},"modified":"2024-01-23T08:12:21","modified_gmt":"2024-01-23T13:12:21","slug":"strand-therapeutics-given-clearance-for-solid-tumour-drug-trial","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/strand-therapeutics-given-clearance-for-solid-tumour-drug-trial\/","title":{"rendered":"Strand Therapeutics given clearance for solid tumour drug trial","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

<\/p>\n

\n
\n
\n Share this article<\/p>\n

<\/span>\n <\/div>\n

<\/p><\/div>\n

<\/p>\n<\/div>\n

<\/p>\n

\n
\n
STX-001 is a programmable mRNA therapy designed to treat patients with solid tumours. Credit: Pixel-Shot \/ Shutterstock.<\/figcaption><\/figure>\n<\/p><\/div>\n
<\/a><\/figure>\n

The US Food and Drug Administration (FDA) has granted clearance for Strand Therapeutics\u2019 investigational new drug (IND) application<\/a> to begin a Phase I clinical trial of STX-001 for solid tumours.<\/p>\n

STX-001 is a programmable messenger ribonucleic acid (mRNA) therapy designed to enhance the efficacy of existing immunotherapies for solid tumours.<\/p>\n

The first-in-human trial will evaluate STX-001, which uses synthetic self-replicating mRNA technology to express the interleukin-12 (IL-12) cytokine within the tumour microenvironment for longer periods.<\/p>\n

STX-001 operates on a multi-mechanistic approach that kills immunogenic cancer cells and boosts the recruitment and activation of T cells and NK cells in the tumour microenvironment.<\/p>\n

It is thought that this approach could improve clinical responses in solid tumour treatments.<\/p>\n

Preclinical data suggest that STX-001 could overcome the limitations of current immunotherapy options.<\/p>\n

\n

Access the most comprehensive Company Profiles
\n on the market, powered by GlobalData. Save hours of research. Gain competitive edge.<\/p>\n